Madhavi Pai Selected Research

A-836339

1/2011	Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats.
1/2009	Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Madhavi Pai Research Topics

Disease

14	Pain (Aches) 01/2022 - 05/2007
8	Neuralgia (Stump Neuralgia) 04/2014 - 05/2007
7	Hyperalgesia 10/2011 - 05/2007
4	Osteoarthritis 07/2013 - 06/2009
4	Postoperative Pain 04/2012 - 05/2007
2	Chronic Pain 04/2014 - 05/2011
1	Fatigue 01/2022
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022
1	Bone Neoplasms (Bone Cancer) 08/2012
1	Arthralgia (Joint Pain) 05/2011
1	Inflammation (Inflammations) 03/2010
1	Peritonitis 03/2010
1	Neurologic Manifestations (Neurological Manifestations) 03/2010

Drug/Important Bio-Agent (IBA)

5	Analgesics (Analgesic Drugs)IBA 04/2014 - 06/2009
5	Freund's AdjuvantIBA 04/2014 - 05/2007
3	CarrageenanIBA 10/2011 - 03/2010
2	Sodium Channels (Sodium Channel)IBA 01/2022 - 05/2007
2	Iodoacetic AcidIBA 07/2013 - 05/2011
2	Histamine (Histamine Dihydrochloride)FDA Link 06/2012 - 03/2010
2	A-836339IBA 01/2011 - 01/2009
2	CannabinoidsIBA 01/2011 - 01/2009
2	Formaldehyde (Formol)FDA Link 10/2010 - 05/2007
2	Capsaicin (Zostrix)FDA Link 01/2009 - 05/2007
1	Voltage-Gated Sodium ChannelsIBA 01/2022
1	venetoclaxIBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	IndazolesIBA 04/2016
1	Ion Channels (Ion Channel)IBA 04/2016
1	Mitogen-Activated Protein Kinase 3IBA 04/2014
1	N2- methyl- N- ((2- (4- (trifluoromethyl)phenyl)octahydrocyclopenta(c)pyrrol- 4- yl)leucinamideIBA 04/2014
1	Biomarkers (Surrogate Marker)IBA 04/2014
1	AcidsIBA 08/2012
1	A-960656IBA 06/2012
1	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 10/2011
1	3- (3- (pyridine- 3- yl)- 1,2,4- oxadiazol- 5- yl)benzonitrileIBA 10/2011
1	Acetates (Acetic Acid Esters)FDA Link 10/2011
1	5-(2-azetidinylmethoxy)-2-chloropyridineIBA 10/2011
1	Mitogen-Activated Protein KinasesIBA 05/2011
1	Messenger RNA (mRNA)IBA 01/2011
1	salicylhydroxamic acid (SHAM)IBA 01/2011
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2011
1	AM 1241IBA 01/2011
1	Histamine H3 Receptors (Histamine H3 Receptor)IBA 10/2010
1	6- ((3- cyclobutyl- 2,3,4,5- tetrahydro- 1H- 3- benzazepin- 7- yl)oxy)- N- methyl- 3- pyridinecarboxamideIBA 10/2010
1	ZymosanIBA 03/2010
1	1- ((5- chloro- 1H- indol- 2- yl)carbonyl)- 4- methylpiperazineIBA 03/2010
1	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2009
1	AmidesIBA 01/2009
1	CB2 Cannabinoid ReceptorIBA 01/2009
1	cyclopropanecarboxylic acidIBA 01/2009
1	Sodium Channel BlockersIBA 05/2007
1	A 803467IBA 05/2007
1	Antisense OligonucleotidesIBA 05/2007

Therapy/Procedure

5	Ligation 06/2012 - 05/2007
2	Analgesia 08/2012 - 04/2012
1	Oral Administration 04/2014
1	Intra-Articular Injections 05/2011